COVend – A new therapy to prevent the progression of COVID-19

A new therapy to prevent

progression to severe ARDS

Biomarker and AI-supported FX06 therapy to prevent the progression from mild and moderate to severe stages of COVID-19

1 M €

ALLOCATED BUDGET

PARTNERS

EUROPEAN COUNTRIES

HOSPITALS

SMEs

Objectives

The aim of the COVend consortium is to deliver a new effective therapy against endothelial damage in ARDS for the clinical management of COVID-19 and other diseases.

Research & Innovation

Some of the technologies involved in the process are OMICs technologies for biomarker profiling, research on endothelial cell damage and AI for Data Analytics and modelling.

Partners

COVend brings together an outstanding consortium of 13 partners from 11 countries with excellent scientific, clinical and organisational expertise to deliver IXION 2.0 study.

IXION 2.0 CLINICAL TRIAL

The clinical trial is the centrepiece of COVend’s work to make FX06 a viable therapy for the clinical management of ARDS in mild and moderate stages, including the prevention of progression to severe disease.

Meet COVend partners

COVend involves partners from all over Europe, with a variety of clinical sites based in different European countries, enabling the delivery of FX06 as a promising candidate to prevent endothelial damage in ARDS for the clinical management of COVID-19 and other diseases during mild and moderate stages. Hear from some COVend partners and discover how COVend is making a difference today!

Major Milestone Reached: COVend’s IXION 2.0 trial enrols its first patients!

We are excited to announce the start of patient enrollment for the IXION 2.0 clinical trial at the Goethe University Hospital Frankfurt. Due to the evolving dynamics of COVID-19, the project’s focus has shifted to investigating the potential benefits of the FX06 drug for patients with acute respiratory distress syndrome (ARDS). Spearheaded by Prof. Zacharowski and Dr. Petra Wülfroth, the co-founder of F4 Pharma in Vienna, the consortium and clinical trial were restructured in record time, underlining the unwavering joint commitment to innovative medical research in critical health conditions.

Groundbreaking research on Idiopathic Systemic Capillary Leak Syndrome: FX06 is Pioneering New Frontiers in Clarkson Disease Treatment

Our COVend consortium member F4 Pharma’s cooperation partners presented groundbreaking research on Idiopathic Systemic Capillary Leak Syndrome (ISCLS), also known as Clarkson disease, first at the 124° Congresso Nazionale of the Societa Italiana di Medicina Interna (SIMI) in October 2023. Now their paper is officially published in Biomedicine & Pharmacotherapy.

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.

FOR INQUIRIES, PLEASE SEND US AN EMAIL AT [email protected]